These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34761331)

  • 1. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    Patil N; Somasundaram E; Waite KA; Lathia JD; Machtay M; Gilbert MR; Connor JR; Rubin JB; Berens ME; Buerki RA; Choi S; Sloan AE; Penas-Prado M; Ashby LS; Blumenthal DT; Werner-Wasik M; Hunter GK; Flickinger JC; Wendland MM; Panet-Raymond V; Robins HI; Pugh SL; Mehta MP; Barnholtz-Sloan JS
    J Neurooncol; 2021 Dec; 155(3):363-372. PubMed ID: 34761331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    Gittleman H; Lim D; Kattan MW; Chakravarti A; Gilbert MR; Lassman AB; Lo SS; Machtay M; Sloan AE; Sulman EP; Tian D; Vogelbaum MA; Wang TJC; Penas-Prado M; Youssef E; Blumenthal DT; Zhang P; Mehta MP; Barnholtz-Sloan JS
    Neuro Oncol; 2017 May; 19(5):669-677. PubMed ID: 28453749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
    Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A
    JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma.
    Kim N; Chang JS; Wee CW; Kim IA; Chang JH; Lee HS; Kim SH; Kang SG; Kim EH; Yoon HI; Kim JW; Hong CK; Cho J; Kim E; Kim TM; Kim YJ; Park CK; Kim JW; Kim CY; Choi SH; Kim JH; Park SH; Choe G; Lee ST; Kim IH; Suh CO
    Strahlenther Onkol; 2020 Jan; 196(1):58-69. PubMed ID: 31489457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
    Gittleman H; Cioffi G; Chunduru P; Molinaro AM; Berger MS; Sloan AE; Barnholtz-Sloan JS
    Neurooncol Adv; 2019; 1(1):vdz007. PubMed ID: 31608326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
    Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
    J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study.
    Kudulaiti N; Zhou Z; Luo C; Zhang J; Zhu F; Wu J
    BMC Surg; 2021 May; 21(1):238. PubMed ID: 33957923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An independently validated survival nomogram for lower-grade glioma.
    Gittleman H; Sloan AE; Barnholtz-Sloan JS
    Neuro Oncol; 2020 May; 22(5):665-674. PubMed ID: 31621885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
    Etcheverry A; Aubry M; Idbaih A; Vauleon E; Marie Y; Menei P; Boniface R; Figarella-Branger D; Karayan-Tapon L; Quillien V; Sanson M; de Tayrac M; Delattre JY; Mosser J
    PLoS One; 2014; 9(9):e104455. PubMed ID: 25233099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
    Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
    J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
    Woo P; Ho J; Lam S; Ma E; Chan D; Wong WK; Mak C; Lee M; Wong ST; Chan KY; Poon WS
    World Neurosurg; 2018 Jul; 115():e375-e385. PubMed ID: 29678708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
    Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
    Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas.
    Yang F; Yang P; Zhang C; Wang Y; Zhang W; Hu H; Wang Z; Qiu X; Jiang T
    Oncotarget; 2017 Jun; 8(26):42974-42982. PubMed ID: 28496000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
    J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.